These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33672644)

  • 1. Systemic Inflammation and Tumour-Infiltrating T-Cell Receptor Repertoire Diversity Are Predictive of Clinical Outcome in High-Grade B-Cell Lymphoma with
    Olschewski V; Witte HM; Bernard V; Steinestel K; Peter W; Merz H; Rieken J; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Grade B-Cell Lymphoma (HGBL) with
    Tsai CC; Su YC; Bamodu OA; Chen BJ; Tsai WC; Cheng WH; Lee CH; Hsieh SM; Liu ML; Fang CL; Lin HT; Chen CL; Yeh CT; Lee WH; Ho CL; Lai SW; Tzeng HE; Hsieh YY; Chang CL; Zheng YM; Liu HW; Yen Y; Whang-Peng J; Chao TY
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational landscape of high-grade B-cell lymphoma with
    Künstner A; Witte HM; Riedl J; Bernard V; Stölting S; Merz H; Olschewski V; Peter W; Ketzer J; Busch Y; Trojok P; Bubnoff NV; Busch H; Feller AC; Gebauer N
    Haematologica; 2022 Aug; 107(8):1850-1863. PubMed ID: 34788985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of translocations involving c-MYC/8q24, BCL2/18q21 and/or BCL6/3q27 genes in patients with follicular lymphoma. Retrospective analysis of single - centre data].
    Misyurina AE; Kravchenko SK; Kovrigina AM; Magomedova AU; Plastinina LV; Obukhova TN; Misyurin AV; Misyurin VA; Grebenuk LA; Babaeva FE; Baryakh EA; Vorobiev AI
    Ter Arkh; 2019 Jul; 91(7):52-62. PubMed ID: 32598736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exhaustion of tumour-infiltrating T-cell receptor repertoire diversity is an age-dependent indicator of immunological fitness independently predictive of clinical outcome in Burkitt lymphoma.
    Rieken J; Bernard V; Witte HM; Peter W; Merz H; Olschewski V; Hertel L; Lehnert H; Biersack H; von Bubnoff N; Feller AC; Gebauer N
    Br J Haematol; 2021 Apr; 193(1):138-149. PubMed ID: 32945554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interim efficacy of a multicenter cohort study for China Net Childhood Lymphoma mature B-cell lymphoma 2017 regimen in the treatment of pediatric High-grade-B cell lymphoma].
    Zhao Y; Huang S; Jia YP; Zhang LP; Duan YL; Jin L; Zhai XW; Wang HS; Hu B; Liu Y; Liu AS; Liu W; Zheng MC; Li F; Sun LR; Yuan XJ; Dai YP; Zhang BX; Jiang L; Wang XG; Wang HM; Zhou CJ; Gao ZF; Zhang YH
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(29):2751-2758. PubMed ID: 39075995
    [No Abstract]   [Full Text] [Related]  

  • 9. High-grade B-cell lymphoma (HGBL)-NOS is clinicopathologically and genetically more similar to DLBCL/HGBL-DH than DLBCL.
    Li S; Qiu L; Xu J; Lin P; Ok CY; Tang G; McDonnell TJ; James You M; Khanlari M; Miranda RN; Medeiros LJ
    Leukemia; 2023 Feb; 37(2):422-432. PubMed ID: 36513804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation of Follicular Lymphoma to a High-Grade B-Cell Lymphoma With MYC and BCL2 Translocations and Overlapping Features of Burkitt Lymphoma and Acute Lymphoblastic Leukemia: A Case Report and Literature Review.
    Bischin AM; Dorer R; Aboulafia DM
    Clin Med Insights Blood Disord; 2017; 10():1179545X17692544. PubMed ID: 28579851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma.
    Chen Y; Cai Q; Chang Y; Zhang M; Li Z
    Front Immunol; 2022; 13():1047115. PubMed ID: 36618391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with
    Uchida A; Isobe Y; Uemura Y; Nishio Y; Sakai H; Kato M; Otsubo K; Hoshikawa M; Takagi M; Miura I
    BMC Clin Pathol; 2017; 17():21. PubMed ID: 29151814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment strategy for high-grade B-cell lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2018; 59(10):2109-2116. PubMed ID: 30305516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-grade B-Cell lymphoma with
    Rogers TS; Gardner JA; Devitt KA
    Autops Case Rep; 2019; 9(3):e2019090. PubMed ID: 31440479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction treatment in high-grade B-cell lymphoma with a concurrent
    Zeremski V; Kropf S; Koehler M; Gebauer N; McPhail ED; Habermann T; Schieppati F; Mougiakakos D
    Front Oncol; 2023; 13():1188478. PubMed ID: 37546419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
    Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
    Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large single-institution retrospective analysis of aggressive B-cell lymphomas according to the 2016/2017 WHO classification.
    Jesionek-Kupnicka D; Braun M; Robak T; Kuncman W; Kordek R
    Adv Clin Exp Med; 2019 Oct; 28(10):1359-1365. PubMed ID: 31518494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
    Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
    Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.